Drug Trial Radar · NCT07211152
Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
150
Actual
Start
Oct 13, 2025
Primary completion
Jun 26, 2026
Study completion Jun 26, 2026
Sponsor
- Lead sponsor
- Sinovac Biotech Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Oct 7, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 39 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, positive controlled phase Ⅲ clinical trial to assess the immunogenicity and safety of Sinovac QIV in pregnant women. A total of 150 healthy pregnant women aged 18\~39 years at 20 to 32 weeks of pregnancy will be enrolled. All participants will be randomized to test group and control group in a ratio of 2:1 and receive one dose of vaccine (0.5 mL) of Sinovac QIV or Vaxigrip QIV, respectively. Blood samples will be collected from participants prior to vaccination and 28 days after vaccination. Moreover, to evaluate trans-placental antibodies, blood samples at the end of the gestation period (delivery) and the cord blood sample will be collected, if applicable. For safety assessment, any immediate adverse events within 30 minutes, solicited local and systemic adverse events within 7 days and unsolicited adverse events within 28 days will be collected. Serious adverse events will be collected within 8 weeks after delivery. Pregnancy and birth outcomes will be collected as well.
Conditions
- Influenza
Interventions
Participants will receive one dose of vaccine (0.5 mL) of Sinovac QIVBiological
Participants will receive one dose of vaccine (0.5 mL) of Sinovac QIV
Vaxigrip QIVBiological
Participants will receive one dose of vaccine (0.5 mL) of Vaxigrip QIV
Primary outcomes
What the sponsor says the trial is designed to measure.
- The seroconversion rates (SCRs) of hemagglutination inhibition (HI) antibodies against each antigen 28 days after vaccination.Time frame: 28 days after vaccination
- The seroprotection rates (SPRs) of hemagglutination inhibition (HI) antibodies against each antigen 28 days after vaccination.Time frame: 28 days after vaccination
- The geometric mean titers (GMTs) of hemagglutination inhibition (HI) antibodies against each antigen 28 days after vaccination.Time frame: 28 days after vaccination
- The geometric mean increase (GMI) of hemagglutination inhibition (HI) antibodies against each antigen 28 days after vaccination.Time frame: 28 days after vaccination
- Incidence of adverse reactions within 28 days after vaccinationTime frame: 28 days after vaccination
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Health Cube Medical Clinics
Mandaluyong, National Capital Region, Philippines
University of the Philippines - Philippine General Hospital (UP-PGH)
Manila, National Capital Region, Philippines
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.